Lack of efficacy of mTOR inhibitors and ACE pathway inhibitors as antifibrotic agents in evolving and established fibrosis in Mdr2⁻/⁻ mice.
about
Tuberous Sclerosis Complex: new criteria for diagnostic work-up and management.Development of an in vitro model to test antifibrotic drugs on primary human liver myofibroblasts.Inconsistent hepatic antifibrotic effects with the iron chelator deferasirox.Long-term administration of tacrolimus and everolimus prevents high cholesterol-high fructose-induced steatosis in C57BL/6J mice by inhibiting de-novo lipogenesis.Ferroportin Expression in Adipocytes Does Not Contribute to Iron Homeostasis or Metabolic Responses to a High Calorie Diet.
P2860
Lack of efficacy of mTOR inhibitors and ACE pathway inhibitors as antifibrotic agents in evolving and established fibrosis in Mdr2⁻/⁻ mice.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Lack of efficacy of mTOR inhib ...... shed fibrosis in Mdr2⁻/⁻ mice.
@en
Lack of efficacy of mTOR inhib ...... shed fibrosis in Mdr2⁻/⁻ mice.
@nl
type
label
Lack of efficacy of mTOR inhib ...... shed fibrosis in Mdr2⁻/⁻ mice.
@en
Lack of efficacy of mTOR inhib ...... shed fibrosis in Mdr2⁻/⁻ mice.
@nl
prefLabel
Lack of efficacy of mTOR inhib ...... shed fibrosis in Mdr2⁻/⁻ mice.
@en
Lack of efficacy of mTOR inhib ...... shed fibrosis in Mdr2⁻/⁻ mice.
@nl
P2093
P2860
P356
P1433
P1476
Lack of efficacy of mTOR inhib ...... shed fibrosis in Mdr2⁻/⁻ mice.
@en
P2093
Amy L Sobbe
C Erika de Guzman
Catherine M Campbell
Darrell H G Crawford
Kim R Bridle
Lesley A Jaskowski
Nishreen Santrampurwala
V Nathan Subramaniam
P2860
P304
P356
10.1111/LIV.12494
P577
2014-03-10T00:00:00Z